PHE377: A novel clinical-stage TRPV1 antagonist devoid of “class” side effects for the treatment of chronic pain syndromes Summary of the Opportunity PharmEste wishes to identify a partner for development and commerc

First Page		Document Content
Date: 2012-11-09 04:33:07 Biology Perception TRPV1 Capsaicin TRPV Neuropathic pain Discovery and development of TRPV1 antagonists Hyperalgesia Piquance Pain Ion channels Mind		PHE377: A novel clinical-stage TRPV1 antagonist devoid of “class” side effects for the treatment of chronic pain syndromes Summary of the Opportunity PharmEste wishes to identify a partner for development and commerc Add to Reading List Source URL: www.pharmeste.com Download Document from Source Website File Size: 63,27 KB Share Document on Facebook

	PRESS RELEASE Zurich, June x 2018 healthbank enters into partnership with Sanovation Health database platform healthbank gains over 200,000 additional users with pain diary apps from Sanovation and makes an important con DocID: 1xUI6 - View Document
	An Initiative for Pain Medication Safety Take Charge of Pain Medication Safety Before you take any type of prescription pain DocID: 1vseO - View Document
	Fibromyalgia and Chronic Pain Title of Abstract Name, Company/University, Country Image DocID: 1vraI - View Document
	FACT SHEET Giving Birth: Labor Pain T DocID: 1vpWK - View Document
	Validating New Technologies to Treat Depression, Pain and the Feeling of Sentient Beings: A Reply to “Neuroscience for the Soul” DocID: 1vpvW - View Document